# Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units (ICUs)

> **NCT00481962** · — · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 180 (actual)

## Conditions studied

- Peritonitis

## Interventions

- **DRUG:** Tygacil

## Key facts

- **NCT ID:** NCT00481962
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2009-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00481962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00481962, "Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units (ICUs)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00481962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*